CureVac’s Market Exit Marks New Chapter for BioNTech

CureVac NL0015436031

The independent, publicly traded chapter for CureVac has closed. The Tübingen-based mRNA pioneer is now wholly owned by BioNTech, concluding its separate listing. For investors, the delisting shifts focus to the future of the combined entity's technology and corporate strategy.

Investor attention now turns entirely to BioNTech shares (Ticker: BNTX). The market anticipates updates in the coming weeks on the merged "Pan-Tumor" programs, which will leverage the intellectual property from both firms. A key measure of the acquisition's success will be the speed at which clinical synergies within the oncology pipeline become evident.

This integration signifies a maturation phase for Germany's biotech sector. By uniting two major European mRNA platforms, BioNTech aims to streamline development and resolve complex patent landscapes. The consolidation is designed to bolster its competitive stance against global rivals such as Moderna.

Acquisition Finalized and Share Exchange

The structural integration was formally completed at the beginning of the month. On January 6, 2026, BioNTech announced it had become the sole owner of CureVac's operational business, finalizing the end of public trading for CureVac stock.

This followed the successful conclusion of a share exchange offer on December 18, 2025, where approximately 86.75% of outstanding CureVac shares were tendered. Within this all-stock transaction, shareholders received 0.05363 BioNTech American Depositary Shares (ADS) for each CureVac share. Consequently, the investment narrative for former CureVac stakeholders is now intrinsically linked to the broader pipeline of the Mainz-based company.

Leadership Appointment to Drive Merger

With the formalities complete, operational integration takes center stage. Aligning with this phase, BioNTech announced a strategically important executive appointment yesterday, Wednesday. Kylie Jimenez will join the board as Chief People Officer, effective March 1, 2026.

Although this appointment occurs at the parent company level, it is critical for the merger process. Jimenez is tasked with realigning the global workforce and managing the integration of the Tübingen sites with BioNTech's headquarters in Mainz. This move is a fundamental component in supporting BioNTech's objective of becoming a leading multi-product cancer therapy company by 2030.

@ boerse-global.de | NL0015436031 CUREVAC’S